Casandra
Casandra Test Code NG22012Version 1 (DRAFT)
Performing Lab
Targeted Solid Tumor NGS Fusion Panel
Also known as: Targeted Solid Tumor Fusion Panel
Clinical Use
Order TestUse
This RNA‑based next‑generation sequencing panel is intended for detection of translocations and gene fusions in solid tumors involving both known and novel fusion partners. It targets key actionable and clinically relevant genes such as ALK, BRAF, FGFR family, MET (including exon 14 skipping), NOTCH1/2, NRG1, NTRK1/2/3, PDGFB, PDGFRA, PDGFRB, RAF1, RET, and ROS1.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Fusion / Rearrangement (19 genes)
ALKBRAFFGFR1FGFR2FGFR3FGFR4METNOTCH1NOTCH2NRG1NTRK1NTRK2NTRK3PDGFBPDGFRAPDGFRBRAF1RETROS1
Result Turnaround Time
21 days
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Paraffin block preferred; or 1 H&E slide plus 5‑10 unstained slides ≥5 µm on positively‑charged slides with 10% NBF fixation; do not use zinc fixatives.